TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types

Immunotherapy with checkpoint inhibitors, such as PD-1/PD-L1 blockage, is becoming standard of practice for an increasing number of cancer types. However, the response rate is only 10%-40%. Thus, identifying biomarkers that could accurately predict the ICI-therapy response is critically important. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jia-Zheng, Yao, Gao-Sheng, Liu, Fei, Tang, Yi-Ming, Li, Peng-Ju, Feng, Zi-Hao, Luo, Jun-Hang, Wei, Jin-Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004558/
https://www.ncbi.nlm.nih.gov/pubmed/35344507
http://dx.doi.org/10.18632/aging.203980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004558/
https://www.ncbi.nlm.nih.gov/pubmed/35344507
http://dx.doi.org/10.18632/aging.203980

Ejemplares similares